The estimated Net Worth of Christopher Dinsmore is at least $452 Tisíc dollars as of 4 January 2024. Dr Dinsmore owns over 7,366 units of Kronos Bio stock worth over $250,504 and over the last 4 years he sold KRON stock worth over $201,774.
Dr has made over 10 trades of the Kronos Bio stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 7,366 units of KRON stock worth $8,692 on 4 January 2024.
The largest trade he's ever made was selling 11,386 units of Kronos Bio stock on 13 December 2021 worth over $140,845. On average, Dr trades about 5,976 units every 84 days since 2020. As of 4 January 2024 he still owns at least 260,969 units of Kronos Bio stock.
You can see the complete history of Dr Dinsmore stock trades at the bottom of the page.
Dr. Christopher Dinsmore is the Chief Scientific Officer at Kronos Bio.
Dr Dinsmore is 54, he's been the Chief Scientific Officer of Kronos Bio since . There are 6 older and 4 younger executives at Kronos Bio. The oldest executive at Kronos Bio, Inc. is Dr. Norbert W. Bischofberger Ph.D., 65, who is the Pres, CEO & Director.
Christopher's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.
Over the last 4 years, insiders at Kronos Bio have traded over $6,434,800 worth of Kronos Bio stock and bought 7,151,111 units worth $30,320,233 . The most active insiders traders include John C Martin, Norbert W Bischofberger a Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of $178,391. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth $732,466.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio executives and other stock owners filed with the SEC include: